{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.50","upperLimit":"2.08","value":"1.750"},{"groupId":"OG001","lowerLimit":"0.50","upperLimit":"2.15","value":"0.765"},{"groupId":"OG002","lowerLimit":"0.50","upperLimit":"8.05","value":"2.020"},{"groupId":"OG003","lowerLimit":"0.50","upperLimit":"3.00","value":"1.500"},{"groupId":"OG004","lowerLimit":"0.50","upperLimit":"2.08","value":"1.485"},{"groupId":"OG005","lowerLimit":"0.50","upperLimit":"2.07","value":"1.550"},{"groupId":"OG006","lowerLimit":"0.50","upperLimit":"7.90","value":"1.500"},{"groupId":"OG007","lowerLimit":"0.50","upperLimit":"7.85","value":"1.520"},{"groupId":"OG008","lowerLimit":"0.50","upperLimit":"4.20","value":"1.490"},{"groupId":"OG009","lowerLimit":"0.45","upperLimit":"4.00","value":"1.050"}]}],"title":"Day 1 (n= 6, 10, 25, 13, 4, 3, 25, 23, 18, 15 )"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.50","upperLimit":"3.07","value":"1.275"},{"groupId":"OG001","lowerLimit":"1.00","upperLimit":"1.63","value":"1.000"},{"groupId":"OG002","lowerLimit":"1.00","upperLimit":"7.95","value":"2.000"},{"groupId":"OG003","lowerLimit":"1.00","upperLimit":"2.00","value":"1.550"},{"groupId":"OG004","lowerLimit":"1.50","upperLimit":"4.17","value":"2.000"},{"comment":"Data was not estimable if evaluable subjects were less than 3 as per the planned decision because only 2 collected values were not sufficient to calculate a reliable estimation.","groupId":"OG005","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"groupId":"OG006","lowerLimit":"0.53","upperLimit":"3.00","value":"1.505"},{"groupId":"OG007","lowerLimit":"1.00","upperLimit":"4.00","value":"1.530"},{"groupId":"OG008","lowerLimit":"0.50","upperLimit":"8.00","value":"1.500"},{"groupId":"OG009","lowerLimit":"0.48","upperLimit":"3.83","value":"1.030"}]}],"title":"Day 15 (n= 6, 9, 15, 9, 3, 1, 16, 17, 13, 10)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"26"},{"groupId":"OG003","value":"14"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"26"},{"groupId":"OG007","value":"24"},{"groupId":"OG008","value":"18"},{"groupId":"OG009","value":"15"}],"units":"Participants"}],"dispersionType":"Full Range","groups":[{"description":"Pimasertib (MSC1936369B) capsule administered at a single oral dose of 15 milligram (mg) on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DE cohort).","id":"OG000","title":"Pimasertib (MSC1936369B) 15mg"},{"description":"Pimasertib (MSC1936369B) capsule administered at a single oral dose of 30 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DE cohort).","id":"OG001","title":"Pimasertib (MSC1936369B) 30mg"},{"description":"Pimasertib (MSC1936369B) capsule administered at a single oral dose of 60 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DE cohort).","id":"OG002","title":"Pimasertib (MSC1936369B) 60mg"},{"description":"Pimasertib (MSC1936369B) capsule administered at a single oral dose of 90 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DE cohort).","id":"OG003","title":"Pimasertib (MSC1936369B) 90mg"},{"description":"Pimasertib (MSC1936369B) capsule administered twice, orally, at a dose of 45 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DE cohort).","id":"OG004","title":"Pimasertib (MSC1936369B) 45mg Twice Daily"},{"description":"Pimasertib (MSC1936369B) capsule administered twice, orally, at a dose of 60 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DE cohort).","id":"OG005","title":"Pimasertib (MSC1936369B) 60mg Twice Daily"},{"description":"Pimasertib (MSC1936369B) capsule administered at a single oral dose of 60 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DSE Cohort).","id":"OG006","title":"TNBC: Pimasertib 60mg Once Daily"},{"description":"Pimasertib (MSC1936369B) capsule administered at a single oral dose of 60 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DSE Cohort).","id":"OG007","title":"NSCLC: Pimasertib 60mg Once Daily"},{"description":"Pimasertib (MSC1936369B) capsule administered at a single oral dose of 60 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DSE Cohort).","id":"OG008","title":"CRC: Pimasertib 60mg Once Daily"},{"description":"Pimasertib (MSC1936369B) capsule administered at a single oral dose of 60 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DSE Cohort).","id":"OG009","title":"MEL: Pimasertib 60mg Once Daily"}],"paramType":"MEDIAN","populationDescription":"The PK analysis set. Here \"n\" signifies the number of subjects evaluable at the specific time points.","reportingStatus":"POSTED","timeFrame":"Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts","title":"Time to Reach Maximum Plasma Concentration (Tmax) of Pimasertib (MSC1936369B)","type":"SECONDARY","unitOfMeasure":"hour"}